Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

# Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone. **Read the full article:** [CNBC](https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*